227. オスラー病 Osler disease Clinical trials / Disease details
臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2017-003272-31-NL (EUCTR) | 18/05/2018 | 11/01/2018 | Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasia | Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia - Itraconazole for epistaxis in HHT patients | Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850 MedDRA version: 20.0;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Sporanox Product Name: Itraconazole | St. Antonius Ziekenhuis | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 25 | Phase 2 | Netherlands |